Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SMMT Summit Therapeutics PLC

Market Closed 02-20 16:00:00 EST

15.94

+0.07

+0.44%

盘后15.90

-0.04-0.25%

19:59 EST

High16.21	Low15.66	Vol2.45M
Open15.68	D1 Closing15.87	Amplitude3.47%
Mkt Cap12.29B	Tradable Cap2.06B	Total Shares771.00M
T/O39.08M	T/O Rate1.90%	Tradable Shares129.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":15.94,"timestamp":1771621200000,"preClose":15.87,"halted":0,"volume":2446790,"hourTrading":{"tag":"盘后","latestPrice":15.9,"preClose":15.94,"latestTime":"19:59 EST","volume":112883,"amount":1799318.9194,"timestamp":1771635598061,"change":-0.04,"changeRate":-0.002509,"amplitude":0.013174},"delay":0,"changeRate":0.004410838059231272,"floatShares":129000000,"shares":771000000,"eps":-1.250689,"marketStatus":"Market Closed","change":0.07,"latestTime":"02-20 16:00:00 EST","open":15.68,"high":16.21,"low":15.66,"amount":39076621.18314,"amplitude":0.034657,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.250689,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":15.87,"preHourTrading":{"tag":"盘前","latestPrice":15.68,"preClose":15.87,"latestTime":"09:29 EST","volume":993,"amount":15765.680274,"timestamp":1771597799999,"change":-0.19,"changeRate":-0.011972,"amplitude":0.025205},"postHourTrading":{"tag":"盘后","latestPrice":15.9,"preClose":15.94,"latestTime":"19:59 EST","volume":112883,"amount":1799318.9194,"timestamp":1771635598061,"change":-0.04,"changeRate":-0.002509,"amplitude":0.013174},"volumeRatio":1.343715982515084,"impliedVol":0.8087,"impliedVolPercentile":0.3108},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"2612495549","title":"Summit Therapeutics Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2612495549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612495549?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:05","pubTimestamp":1771365911,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results and provide an operational update on Monday, February 23, 2026, after the market closes. The company will host a live webcast of the earnings conference call at 4:30pm ET, accessible through the Summit Therapeutics website. An archived edition of the session will also be available on their website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL9yKHmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"gpt_icon":0},{"id":"2610697666","title":"Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2610697666","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610697666?lang=en_us&edition=fundamental","pubTime":"2026-02-10 11:20","pubTimestamp":1770693648,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. previously announced that the FDA accepted for filing its Biologics License Application for ivonescimab plus chemotherapy in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC after tyrosine kinase inhibitor therapy, assigning a PDUFA action date of November 14, 2026.\nBeyond this U.S. filing, Summit and partner Akeso have broadened ivonescimab’s late-stage program across multiple Phase III trials and tumor types, underscoring a concerted push to position...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-smmt-is-up-65-after-fda-accepts-ivonesci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-smmt-is-up-65-after-fda-accepts-ivonesci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SMMT","LU2488822045.USD","BK4139"],"gpt_icon":0},{"id":"2609482043","title":"Assessing Summit Therapeutics (SMMT) Valuation After FDA Acceptance Of Ivonescimab BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2609482043","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609482043?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:34","pubTimestamp":1770244446,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) recently reported that the FDA accepted its Biologics License Application for ivonescimab in EGFR mutated non small cell lung cancer and set a PDUFA action date of November 14, 2026.\nSee our latest analysis for Summit Therapeutics.\nSummit Therapeutics’ latest FDA milestone comes after a mixed stretch for investors, with a 1 year total shareholder return decline of 29.24% but a very large 3 year total shareholder return. Recent 30 and 90 day share price returns of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-fda-accep","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-fda-accep","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"2607021734","title":"Summit Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2607021734","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607021734?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:30","pubTimestamp":1769808611,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. has announced the grant of stock options to 20 new employees, totaling up to 257,368 shares of common stock. The options have a ten-year term with an exercise price of $16.56 per share, matching the closing price on the grant date of January 26, 2026. Vesting will occur in equal annual installments over a four-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on January 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDLXQH3v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"gpt_icon":0},{"id":"2607212150","title":"Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607212150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607212150?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:30","pubTimestamp":1769808600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA3GPG42:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SMMT","LU2488822045.USD"],"gpt_icon":0},{"id":"2607094432","title":"Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Ceribell, Inc. (CBLL) and Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607094432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607094432?lang=en_us&edition=fundamental","pubTime":"2026-01-30 15:41","pubTimestamp":1769758877,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Talkspace (TALK – Research Report), Ceribell, Inc. (CBLL – Resear...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-talkspace-talk-ceribell-inc-cbll-and-summit-therapeutics-smmt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-talkspace-talk-ceribell-inc-cbll-and-summit-therapeutics-smmt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4196","LU0029874061.USD","CBLL","BK4588","TALK","LU2488822045.USD","BK4137","BK4581","LABU","HCSG","LU0128526141.USD","BK4585","BK4139","SMMT","XBI","BK4082"],"gpt_icon":0},{"id":"2607201867","title":"Reassessing Summit Therapeutics (SMMT) After Sharp Pullback And DCF Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2607201867","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607201867?lang=en_us&edition=fundamental","pubTime":"2026-01-30 11:39","pubTimestamp":1769744367,"startTime":"0","endTime":"0","summary":"If you are wondering whether Summit Therapeutics' share price still reflects its true worth after a volatile few years, you are not alone.\nThe stock trades at US$15.40, with returns of an 11.3% decline over the past week, 11.9% decline over the past month, 12.1% decline year to date and 31.1% decline over the last year, set against a very large gain of around 3x over three years and 99.5% gain over five years.\nRecent news around Summit Therapeutics has focused on its position within the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/reassessing-summit-therapeutics-smmt-after-sharp-pullback-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/reassessing-summit-therapeutics-smmt-after-sharp-pullback-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2488822045.USD","FCF","DCF","BK4139","SMMT","BK4211"],"gpt_icon":0},{"id":"2607033193","title":"BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2607033193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607033193?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:18","pubTimestamp":1769696315,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed MartinEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL6N3YU0S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIAV","TSLR","VLO","BHP.AU","TSLL","RCL","RIO.UK","TSL","TSLZ","TSLG","JOBY","RIO.AU","WHR","TSLS","CAT","UNCY","TSLY","TSLI","TSLT","IBM","TSLO","TSLQ","MO","IP","BX","TSLP","TSYY","DOW","TSLW","SHW","VENU","LUV","LMT","XRX","GUTS","TSII","HON","SMMT","SCCO","MSFD"],"gpt_icon":1},{"id":"2607087753","title":"BUZZ-Summit rises after FDA accepts marketing application for lung cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087753","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607087753?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:07","pubTimestamp":1769692035,"startTime":"0","endTime":"0","summary":"BUZZ-Summit rises after FDA accepts marketing application for lung cancer drug** Shares of drug developer Summit Therapeutics SMMT.O rise 3.71% to $16.22 premarket** Co says the U.S. Food and Drug Administration has accepted its application to market its experimental drug to treat lung cancer  ** Reports mixed results from patient subgroups in a longer-term follow-up of its late-stage trial in September** The therapy is an antibody designed to block a protein called PD-1, which helps the body's immune system fend off cancer; Keytruda also targets the same protein  ** The health regulator has assigned a new Prescription Drug User Fee Act  target action date for November 14, 2026 - SMMT** Stock fell ~2% in 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4N3YU1S0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"gpt_icon":0},{"id":"2607082801","title":"Summit Therapeutics Shares up 5.5% Premarket After US FDA Accepts Co's Application for Ivonescimab Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607082801?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:34","pubTimestamp":1769690079,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU0LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SMMT","LU2488822045.USD"],"gpt_icon":0},{"id":"2607837082","title":"FDA Accepts Biologics License Application for Summit Therapeutics' Ivonescimab in EGFR-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2607837082","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607837082?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:30","pubTimestamp":1769689847,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. announced that the U.S. Food & Drug Administration  has accepted for filing its Biologics License Application  for ivonescimab in combination with chemotherapy for the treatment of patients with epidermal growth factor receptor -mutated locally advanced or metastatic non-squamous non-small cell lung cancer  following tyrosine kinase inhibitor  therapy. The FDA has set a Prescription Drug User Fee Act  target action date of November 14, 2026. The application is based on results from the Phase III HARMONi trial, which evaluated ivonescimab plus platinum-doublet chemotherapy compared to placebo plus chemotherapy in this patient population. The FDA will conduct a complete review of the application according to its established review management principles and practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDLc1ZLhV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"gpt_icon":0},{"id":"2607840180","title":"Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (Bla) Seeking Approval for Ivonescimab in Combination With Chemotherapy in Treatment of Patients With Egfrm Nsclc Post-Tki Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2607840180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607840180?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:30","pubTimestamp":1769689800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUA8RHJDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"2607084011","title":"Summit Therapeutics Inc: Pdufa Goal Action Date of November 14, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084011?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:30","pubTimestamp":1769689800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUA8RHJDV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"2605109233","title":"BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2605109233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605109233?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:50","pubTimestamp":1768996221,"startTime":"0","endTime":"0","summary":"BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'** Guggenheim starts coverage on drugmaker Crescent Biopharma CBIO.O with \"buy\"; sets PT at $35** Says CBIO has a compelling investment thesis as it awaits long-term data for its experimental lung cancer treatment, CR-001, in Q1 2027 ** Says this will provide a clear comparable to Summit's SMMT.O ivonescimab, which belongs to a similar class of drugs** CBIO's proprietary antibody-drug conjugate  pipeline, known as \"guided-missile\" cancer drugs, could generate independent value as monotherapy and be synergistic with CR-001 in earlier solid tumor treatment settings - Brokerage** \"We see CBIO as set up to be awarded significant value both from what the company is replicating and what the company is pioneering\" - Brokerage** As of last close, CBIO stock down 52.37% in the past 12 months ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM0ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","CBIO","SMMT","BK4139"],"gpt_icon":0},{"id":"2604971355","title":"Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604971355","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604971355?lang=en_us&edition=fundamental","pubTime":"2026-01-19 01:31","pubTimestamp":1768757460,"startTime":"0","endTime":"0","summary":"Regencell led last week's large-cap losers as Figma, Atlassian and Trip.com slid on downgrades, probes and broader tech weakness.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/18/Munich--Bavaria--Germany---March-31-2023.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/18/Munich--Bavaria--Germany---March-31-2023.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/01/49985495/trip-com-regencell-bioscience-and-atlassian-are-among-top-10-large-cap-losers-last-week-jan-12-jan-16-are-the-others-in-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/01/49985495/trip-com-regencell-bioscience-and-atlassian-are-among-top-10-large-cap-losers-last-week-jan-12-jan-16-are-the-others-in-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0329678170.USD","GWRE","LU0965508806.USD","LU1989772923.USD","LU0097036916.USD","BK4023","LU0426417589.USD","GPIQ","IE00B894F039.SGD","LU0689626769.HKD","LU1720051017.SGD","LU0912757837.SGD","RGC","BK4534","PSQ","IE00BPRC5H50.USD","LU1037948541.HKD","IE00B19Z8W00.USD","LU0738911758.USD","LU0650527681.SGD","LU1868837722.USD","LU2089284900.SGD","09961","LU1791710400.SGD","BK4532","LU0342679015.USD","LU0795875169.SGD","LU0106831901.USD","LU0348825331.USD","LU1074936037.SGD","LU0157215616.USD","LU0370786039.SGD","LU1791710582.SGD","SMMT","LU0861579265.USD","BK4504","LU0098860793.USD","LU0314104364.USD","BK4139","IE00BQXX3D17.EUR","LU0289961442.SGD","LU2063271972.USD","SG9999000475.SGD","LU1804176565.USD","BK4561","LU0963586101.USD","LU2111349929.HKD","LU0348827113.USD","LU0315179316.USD","LU0327786744.USD","IE00B5MMRT66.SGD","LU0143863198.USD","LU0158827781.USD","LU0261950470.USD","LU2399975544.HKD","TSYW.SI","LU0828237510.HKD","BK4608","QLD","IE0009356076.USD","QQQY","LU1794554557.SGD","BK4585","BK4531","BK4566","LU0971096721.USD","LU2089283258.USD","QQQJ","TCOM","LU0889565833.HKD","IE00BMPRXN33.USD","LU1989764748.USD","LU0593848301.USD","QYLG","LU0006306889.USD","LU0267386448.USD","BK4516","SQQQ","LU0572944931.SGD","LU1242518857.USD","LU1236620834.HKD","LU0965509283.SGD","LU1363072403.SGD","BK4528","NTNX","LU2065169927.USD","LU0882574139.USD","LU1023057109.AUD","LU2488822045.USD","IE00BZ9MQY76.HKD","LU1242518931.SGD","LU1244550494.USD","LU0048580855.USD","BK4551","LU1037948897.HKD","LU0795875086.SGD","IE00BQXX3C00.GBP","LU0823434740.USD","LU0061474960.USD","SG9999002224.SGD","TEAM","LU0994945656.USD","BK4548","LU1778281490.HKD","LU0039217434.USD","IE00BMPRXR70.SGD","LU0051755006.USD","LU0320765646.SGD","LU0528227936.USD","LU0359202008.SGD","LU0640476718.USD","LU0737861772.HKD","LU2065171402.SGD","LU2095319765.USD","LU2347655156.SGD","NQmain","SG9999002232.USD","LU0719512351.SGD","LU1043141123.HKD","IE00BZ1G4Q59.USD","LU0594300419.USD","LU1674673691.USD","LU0965509010.AUD","IE00B19Z9Z06.USD","LU1162221912.USD","LU2210149790.SGD","LU0106252389.USD","LU1244550577.SGD","LU2065171311.SGD","IE00B3M56506.USD","LU1732800096.USD","LU2265009873.SGD","LU0049853897.USD","LU1674673428.USD","LU1043141396.HKD","LU1868837565.USD","LU0109392836.USD","LU2054465674.USD","IE00B5949003.HKD","BK4539","USAW.SI","LU1121112475.USD","BK4533","BK4607","BK4613","LU0345774391.USD","BK4127","LU1803068979.SGD","BK4588","LU0979878070.USD","IE00BKVL7J92.USD","BK4567","LU0456827905.SGD","IE00B19Z9P08.USD","LU1934455194.USD","IE00B19Z8X17.USD","BK4142","INTU","LU0210526637.USD","BK4526","LU1720050803.USD","QQQE","LU0949170772.SGD","LU0661504455.SGD","LU1934455277.USD","LU1548497426.USD","LU1815333072.USD","LU1961090484.USD","LU0143863784.USD","LU2357305700.SGD","QID","QQQM","BK4581","LU0048575426.USD","LU1989764664.SGD","LU2210150020.SGD","QYLD","LU0359201885.HKD","LU0557290698.USD","LU0266013472.USD","IE00B543WZ88.USD","IE00BQXX3F31.USD","LU0957791311.USD","LU2023251221.USD","DOCU","LU2271345857.HKD","TQQQ","LU2133065610.SGD","LU0082616367.USD","LU0965509101.SGD","LU0359201612.USD","LU0158827948.USD","LU1934455863.HKD","LU0228659784.USD","LU0289739343.SGD","HUBS","LU2355687059.USD","LU0251143458.SGD","IE00B0JY6N72.USD","LU0124676726.USD","LU1366333091.USD","LU2028103732.USD","LU0011850046.USD","SG9999001424.SGD","IE00B19Z9505.USD","LU0823434583.USD","LU0225283273.USD","LU1720051108.HKD","LU2152927971.USD","LU1280957306.USD","LU2065170008.USD","LU0329678337.USD","LU1732799900.SGD","LU1868838027.USD","LU0511384066.AUD","LU0234570918.USD","GB00BDT5M118.USD","LU1244550221.USD","LU0426412945.USD","NVIW.SI","LU0106261372.USD","LU0417516902.SGD","LU0345774631.USD","LU1989772840.SGD","BK4007","LU0561508036.HKD","LU1668664300.SGD","USJW.SI","LU1236620750.USD","MNQmain"],"gpt_icon":1},{"id":"2603984238","title":"Alpha Buying: Managing Biotech Risk With Insider Clues","url":"https://stock-news.laohu8.com/highlight/detail?id=2603984238","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603984238?lang=en_us&edition=fundamental","pubTime":"2026-01-16 00:32","pubTimestamp":1768494720,"startTime":"0","endTime":"0","summary":"Biotech stocks have a way of making smart people do dumb things. It starts innocently enough.You read about a \"breakthrough\" that sounds like it came straight out of science fiction. A tiny company with a tiny market cap is working on a therapy that could change the standard of care.You picture the chart before you even open it. A little line. Then a rocket ship.You buy a starter position because you do not want to miss it, and you tell yourself you will add later if the story keeps getting better.And then biotech does what biotech always does. It reminds you that in this corner of the market, the business is not the product. The business is the trial.Then there is the information environment, which is a polite way of saying biotech is a narrative factory. The science is complex, the milestones are technical, and the incentives are obvious. Management wants to keep the story alive. Analysts want access. Retail investors want hope. Soci","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/Stock-Market-Analysis-With-Candlestick-C.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/Stock-Market-Analysis-With-Candlestick-C.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/01/49941880/alpha-buying-managing-biotech-risk-with-insider-clues","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/01/49941880/alpha-buying-managing-biotech-risk-with-insider-clues","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CRVO","SMMT","LU2488822045.USD","BK4139","ANNX"],"gpt_icon":0},{"id":"2603988700","title":"Jefferies Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603988700?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:36","pubTimestamp":1768484206,"startTime":"0","endTime":"0","summary":"In a report released today, from Jefferies maintained a Buy rating on Summit Therapeutics, with a price target of $42.00. In addition to Jefferies,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-summit-therapeutics-smmt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-summit-therapeutics-smmt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMT"],"gpt_icon":0},{"id":"2602511437","title":"Summit Therapeutics Files Marketing Application for Lung Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511437","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511437?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:44","pubTimestamp":1768218278,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  announced on Monday that it has submitted a marketing application to the US Food and Drug Administration, seeking approval for its experimental drug, ivonescimab, in combination with chemotherapy for the second-line or later treatment of certain patients with a type of non-small cell lung cancer.The company said the submission is based on results from a phase III trial.If the application is accepted under standard review timelines, Summit said it expects an FDA decision in Q4.As of December 31, 2025, Summit stated that its preliminary unaudited cash, cash equivalents, and short-term investments totaled approximately $710 million, pending completion of financial closing procedures.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","LENZ","BK4211","BK4139","SMMT","BK4539","SMMF","BK4007"],"gpt_icon":0},{"id":"2602955519","title":"Summit Therapeutics and GSK Partner to Evaluate Ivonescimab and B7-H3 ADC in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2602955519","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602955519?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:15","pubTimestamp":1768216517,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. has announced a clinical trial collaboration with GSK to evaluate the combination of ivonescimab, Summit’s investigational PD-1/VEGF bispecific antibody, with GSK’s novel B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan , across multiple solid tumor types, including small cell lung cancer. Under the agreement, Summit will provide ivonescimab for the study, while GSK will oversee clinical operations. Both companies will retain rights to their respective products, and the agreement is mutually non-exclusive. Patient dosing in the study is expected to begin in mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6lyPNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4139","SMMT"],"gpt_icon":0},{"id":"2602519988","title":"Summit Therapeutics Inc - to Supply Ivonescimab, GSK to Manage Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602519988?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:15","pubTimestamp":1768216500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA78DN6Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","BK4139","SMMT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":0.0655},{"period":"1month","weight":-0.054},{"period":"3month","weight":-0.0154},{"period":"6month","weight":-0.3916},{"period":"1year","weight":-0.3088},{"period":"ytd","weight":-0.0886}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.031619},{"month":3,"riseRate":0.4,"avgChangeRate":0.028993},{"month":4,"riseRate":0.454545,"avgChangeRate":0.034483},{"month":5,"riseRate":0.545455,"avgChangeRate":0.099475},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.086722},{"month":7,"riseRate":0.636364,"avgChangeRate":0.088383},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.007003},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Summit Therapeutics PLC(SMMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Summit Therapeutics PLC(SMMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}